Why is Samrat Pharma falling/rising?

As of 18-Jul, Samrat Pharmachem Ltd's stock price is currently at Rs 370.50, reflecting a decline of Rs 8.5 or 2.24%. The stock has been underperforming, having fallen consecutively for the last two days with a total drop of 3.72%. It opened lower today with a loss of 2.11% and reached an intraday low of Rs 370, indicating a challenging trading environment. Despite a strong year-over-year return of 4.07% and significant profit growth of 229.2%, the stock's performance has been hindered by a decrease in foreign institutional investor (FII) holdings to 0% this quarter, which may signal reduced confidence among larger investors. Additionally, the stock's recent delivery volume has decreased by 31.47%, suggesting a drop in investor participation.
In the broader market context, the stock has shown a positive return of 1.27% over the past week, while the benchmark Sensex has declined by 0.90%. However, the year-to-date performance reveals a concerning trend, with Samrat Pharmachem down 3.02% compared to the Sensex's gain of 4.63%. This underperformance is compounded by the company's flat operating profit growth of 8.89% over the last five years and disappointing quarterly results, which have likely contributed to the stock's recent decline. The stock's liquidity remains adequate, but the overall sentiment appears to be negative, influenced by both internal financial challenges and external market dynamics.